

## REMARKS

This paper is submitted in response to the Office Action Summary (“Office Action”) mailed May 31, 2007 regarding SEQ ID NO. requirements. The Examiner indicated that the amino acid sequence in the middle of FIG. 3 was in need of SEQ ID NOS, however, Applicants believe that the Examiner is in error with this reference. Applicants believe the Examiner meant to refer to FIG. 2. Therefore, Applicants are providing herewith a replacement Sequence Listing with regard to the amino acid sequence disclosed in FIG. 2. The specification has been amended to replace paragraph [0331] to insert the corresponding SEQ ID NOS for the sequences disclosed in FIG. 2. Applicants assert that no new matter has entered in the substitute Sequence Listing or replacement paragraph.

## STATEMENT REGARDING CONTENTS OF SEQUENCE LISTING UNDER 37 CFR §§1.821- 1.825

Applicants enclose a computer readable copy of the Sequence Listing for the instant application as well as a substitute paper copy of the Sequence Listing. In accordance with 37 CFR §1.821 and §1.825, Applicants’ undersigned agent states that both the computer readable copy and the substitute paper copy of the Sequence Listing submitted herewith are the same, and include no new matter.

No fee should be due with this communication. However, the Commissioner is hereby authorized to charge any fee required with this communication to Deposit Account 11-0404.

Dated: June 22, 2007

Respectfully submitted,  
KELLEY DRYE & WARREN LLP  
Attorneys and Agents for Applicants

By: Thelma A. Chen Cleland  
Thelma A. Chen Cleland, Reg. No. 40,948  
JOHN N. COULBY, Reg. No. 43,565  
3050 K Street, N.W., Suite 400  
Washington D.C. 20007  
Tel. (202) 342-8400